skip to content
Lurasidone hydrochloride (Latuda) : management of manifestations of schizophrenia. Preview this item
ClosePreview this item
Checking...

Lurasidone hydrochloride (Latuda) : management of manifestations of schizophrenia.

Author: Canadian Agency for Drugs and Technologies in Health,
Publisher: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2014.
Series: Common drug review clinical review report.
Edition/Format:   eBook : Document : English
Summary:
Lurasidone (Latuda) is an atypical antipsychotic (AAP) indicated for the management of patients with clinical manifestations of schizophrenia. The manufacturer has submitted a resubmission requesting reimbursement for the 40 mg, 80 mg, and 120 mg strengths for the management of the manifestations of schizophrenia; the original approved indication and listing request for lurasidone when the drug was initially  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

 

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Review
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Canadian Agency for Drugs and Technologies in Health,
OCLC Number: 888343050
Notes: Title from title screen.
Description: 1 online resource : illustrations.
Series Title: Common drug review clinical review report.

Abstract:

Lurasidone (Latuda) is an atypical antipsychotic (AAP) indicated for the management of patients with clinical manifestations of schizophrenia. The manufacturer has submitted a resubmission requesting reimbursement for the 40 mg, 80 mg, and 120 mg strengths for the management of the manifestations of schizophrenia; the original approved indication and listing request for lurasidone when the drug was initially submitted to the Common Drug Review (CDR) in 2012 was for the acute treatment of patients with schizophrenia. In January 2013, the Canadian Drug Expert Committee (CDEC) issued a recommendation that lurasidone not be listed. The key reason for the recommendation was a lack of evidence from randomized controlled trials (RCTs) to establish the comparative efficacy of lurasidone relative to other AAPs for the acute treatment of schizophrenia. The original CDR review included nine RCTs investigating the efficacy and safety of lurasidone for the treatment of schizophrenia. Seven of the trials were placebo-controlled, acute-treatment trials of six weeks duration designed to assess the efficacy of various doses of lurasidone ranging from 20 mg to 160 mg daily (Studies: 6 [N = 149], 196 [N = 180], 229, [N = 500], 231 [N = 478], 233 [N = 488], 2 [N = 460], and 49 [N = 356]). The remaining two trials (Study 237 and Study 254) were performed in stable patients. Four of the acute-treatment trials (Studies 2, 49, 231, and 233) included active comparators to verify assay sensitivity, but none were designed to compare lurasidone with the active treatments. In May 2013, the manufacturer resubmitted lurasidone seeking a listing recommendation for the acute treatment of schizophrenia. The basis of the resubmission is: an indirect comparison (IDC) of lurasidone, aripiprazole, and ziprasidone; an open-label study of patients switched to lurasidone from another antipsychotic; the publication of Study 234, an open-label extension study of Study 233 (reviewed as a Supplemental Issue in the original CDR review based on unpublished information); Study 231E, an open-label extension of Study 231; and a lower confidential price.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/888343050> # Lurasidone hydrochloride (Latuda) : management of manifestations of schizophrenia.
    a schema:Book, schema:MediaObject, schema:CreativeWork ;
   library:oclcnum "888343050" ;
   library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
   schema:about <http://experiment.worldcat.org/entity/work/data/2056358073#Topic/treatment_outcome> ; # Treatment Outcome
   schema:about <http://experiment.worldcat.org/entity/work/data/2056358073#Topic/thiazoles_therapeutic_use> ; # Thiazoles--therapeutic use
   schema:about <http://experiment.worldcat.org/entity/work/data/2056358073#Topic/antipsychotic_agents_therapeutic_use> ; # Antipsychotic Agents--therapeutic use
   schema:about <http://experiment.worldcat.org/entity/work/data/2056358073#Topic/isoindoles_therapeutic_use> ; # Isoindoles--therapeutic use
   schema:about <http://experiment.worldcat.org/entity/work/data/2056358073#Topic/schizophrenia_drug_therapy> ; # Schizophrenia--drug therapy
   schema:bookFormat schema:EBook ;
   schema:contributor <http://experiment.worldcat.org/entity/work/data/2056358073#Organization/canadian_agency_for_drugs_and_technologies_in_health> ; # Canadian Agency for Drugs and Technologies in Health,
   schema:datePublished "2014" ;
   schema:description "Lurasidone (Latuda) is an atypical antipsychotic (AAP) indicated for the management of patients with clinical manifestations of schizophrenia. The manufacturer has submitted a resubmission requesting reimbursement for the 40 mg, 80 mg, and 120 mg strengths for the management of the manifestations of schizophrenia; the original approved indication and listing request for lurasidone when the drug was initially submitted to the Common Drug Review (CDR) in 2012 was for the acute treatment of patients with schizophrenia. In January 2013, the Canadian Drug Expert Committee (CDEC) issued a recommendation that lurasidone not be listed. The key reason for the recommendation was a lack of evidence from randomized controlled trials (RCTs) to establish the comparative efficacy of lurasidone relative to other AAPs for the acute treatment of schizophrenia. The original CDR review included nine RCTs investigating the efficacy and safety of lurasidone for the treatment of schizophrenia. Seven of the trials were placebo-controlled, acute-treatment trials of six weeks duration designed to assess the efficacy of various doses of lurasidone ranging from 20 mg to 160 mg daily (Studies: 6 [N = 149], 196 [N = 180], 229, [N = 500], 231 [N = 478], 233 [N = 488], 2 [N = 460], and 49 [N = 356]). The remaining two trials (Study 237 and Study 254) were performed in stable patients. Four of the acute-treatment trials (Studies 2, 49, 231, and 233) included active comparators to verify assay sensitivity, but none were designed to compare lurasidone with the active treatments. In May 2013, the manufacturer resubmitted lurasidone seeking a listing recommendation for the acute treatment of schizophrenia. The basis of the resubmission is: an indirect comparison (IDC) of lurasidone, aripiprazole, and ziprasidone; an open-label study of patients switched to lurasidone from another antipsychotic; the publication of Study 234, an open-label extension study of Study 233 (reviewed as a Supplemental Issue in the original CDR review based on unpublished information); Study 231E, an open-label extension of Study 231; and a lower confidential price."@en ;
   schema:exampleOfWork <http://worldcat.org/entity/work/id/2056358073> ;
   schema:genre "Review"@en ;
   schema:inLanguage "en" ;
   schema:isPartOf <http://experiment.worldcat.org/entity/work/data/2056358073#Series/common_drug_review_clinical_review_report> ; # Common drug review clinical review report.
   schema:name "Lurasidone hydrochloride (Latuda) : management of manifestations of schizophrenia."@en ;
   schema:productID "888343050" ;
   schema:url <http://www.ncbi.nlm.nih.gov/books/NBK195622/> ;
   schema:url <https://www.ncbi.nlm.nih.gov/books/NBK195622> ;
   wdrs:describedby <http://www.worldcat.org/title/-/oclc/888343050> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/2056358073#Organization/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health,
    a schema:Organization ;
   schema:name "Canadian Agency for Drugs and Technologies in Health," ;
    .

<http://experiment.worldcat.org/entity/work/data/2056358073#Series/common_drug_review_clinical_review_report> # Common drug review clinical review report.
    a bgn:PublicationSeries ;
   schema:hasPart <http://www.worldcat.org/oclc/888343050> ; # Lurasidone hydrochloride (Latuda) : management of manifestations of schizophrenia.
   schema:name "Common drug review clinical review report." ;
   schema:name "Common drug review clinical review report" ;
    .

<http://experiment.worldcat.org/entity/work/data/2056358073#Topic/antipsychotic_agents_therapeutic_use> # Antipsychotic Agents--therapeutic use
    a schema:Intangible ;
   schema:name "Antipsychotic Agents--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2056358073#Topic/isoindoles_therapeutic_use> # Isoindoles--therapeutic use
    a schema:Intangible ;
   schema:name "Isoindoles--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2056358073#Topic/schizophrenia_drug_therapy> # Schizophrenia--drug therapy
    a schema:Intangible ;
   schema:name "Schizophrenia--drug therapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2056358073#Topic/thiazoles_therapeutic_use> # Thiazoles--therapeutic use
    a schema:Intangible ;
   schema:name "Thiazoles--therapeutic use"@en ;
    .

<http://www.worldcat.org/title/-/oclc/888343050>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
   schema:about <http://www.worldcat.org/oclc/888343050> ; # Lurasidone hydrochloride (Latuda) : management of manifestations of schizophrenia.
   schema:dateModified "2017-09-03" ;
   void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.